One Diagnosis, Different Diseases? Researchers Uncover Distinct Types of Gestational Diabetes

Gestational diabetes is usually treated as a single diagnosis, but growing evidence suggests the biology behind it can vary considerably from one patient to another. Researchers studying gestational diabetes phenotypes have identified metabolic patterns involving differences in insulin resistance, insulin secretion, or both. These findings raise an important question: Could two patients who meet the same diagnostic criteria actually have meaningfully different forms of gestational diabetes?

If so, recognizing those differences could eventually change how clinicians assess pregnancy risks, select treatments, and plan follow-up after delivery.

Table of Contents

• Why Gestational Diabetes May Not Be One Condition
• What Researchers Have Learned About GDM Phenotypes
• Pregnancy and Long-Term Diabetes Risk
• Could GDM Treatment Become More Personalized?
• Conclusion
• Frequently Asked Questions

Why Different Forms of Gestational Diabetes May Matter

Gestational diabetes mellitus (GDM) develops when insulin production cannot adequately compensate for the metabolic demands of pregnancy. However, the reasons for that imbalance are not identical in every patient.

Researchers have therefore explored whether GDM can be separated into physiologic subtypes. One influential approach classifies patients according to insulin sensitivity and insulin secretion. This produces groups characterized primarily by insulin resistance, impaired insulin secretion, or a combination of both abnormalities.

In a study of 809 pregnant women, researchers found substantial metabolic heterogeneity among those diagnosed with GDM. About 51% of GDM cases had a predominant insulin sensitivity defect, while approximately 30% had a predominant insulin secretion defect. Importantly, the insulin-resistant group had higher BMI and fasting glucose levels and delivered larger infants. They also experienced more GDM-associated adverse pregnancy outcomes. The study was published in Diabetes Care.

These findings suggest that glucose levels alone may not tell the entire metabolic story. Consequently, recognizing distinct GDM subtypes could help explain why pregnancy outcomes vary among patients who share the same diagnosis.

Distinct GDM Types Show Different Metabolic Patterns

The concept of GDM subtypes has expanded beyond the original insulin sensitivity and secretion model. More recent research has used larger datasets and clustering methods to identify groups of patients with different metabolic profiles.

For example, a clustering study of women who developed GDM identified three distinct groups. The clusters differed in characteristics such as maternal age, pre-pregnancy BMI, fasting glucose, and glucose responses during an oral glucose tolerance test. Notably, some metabolic differences were already detectable during early pregnancy.

Meanwhile, research using data from the Hyperglycemia and Adverse Pregnancy Outcome study has provided further evidence that physiologic GDM subtypes may be associated with different outcomes. Investigators classified GDM as insulin-deficient, insulin-resistant, or mixed-defect and examined newborn and childhood outcomes.

Together, these studies support a broader view of GDM. Rather than representing one uniform metabolic disorder, the diagnosis may capture several pathways that ultimately produce elevated blood glucose.

However, there is an important scientific debate here. A perspective published in the American Diabetes Association journal Diabetes cautioned against interpreting insulin sensitivity and secretion as completely separate causes. Because insulin secretion normally changes in response to insulin sensitivity, researchers must consider the relationship between the two. In that analysis, different proposed subgroups shared evidence of impaired beta-cell compensation despite differences in insulin resistance.

Therefore, GDM phenotyping may be useful, but the precise biological meaning of each phenotype remains under investigation.

Pregnancy Complications and Future Diabetes Risk

Perhaps the most clinically important question is whether these metabolic differences translate into different clinical risks.

Evidence suggests they may, particularly during pregnancy. In the earlier Diabetes Care study, patients with predominantly impaired insulin sensitivity had larger infants and a higher frequency of GDM-related adverse outcomes than women with normal glucose tolerance. In contrast, those with predominantly impaired insulin secretion had outcomes that were more similar to the normal-glucose group.

Other research has produced similar signals. One study examining physiologic subtypes of gestational glucose intolerance found that the insulin-resistant subtype was associated with increased odds of delivering a large-for-gestational-age infant compared with normal glucose tolerance, even after adjustment for several factors.

Still, pregnancy risk is only part of the story. GDM is also an important warning sign for later metabolic disease, including prediabetes and type 2 diabetes.

Interestingly, metabolic subtypes may not separate long-term risk as clearly as they separate some pregnancy outcomes. A prospective study of 613 women evaluated glucose tolerance during pregnancy and again at three and 12 months postpartum. Both the insulin-sensitivity and insulin-secretion GDM subtypes predicted higher rates of prediabetes or diabetes compared with women without GDM. However, the postpartum prevalence rates were similar between the two major GDM subtypes.

That finding carries an important practical message. A phenotype associated with fewer pregnancy complications should not automatically be considered metabolically harmless after delivery.

Could Gestational Diabetes Care Become More Personalized?

Today, clinicians generally diagnose and manage GDM according to glucose-based criteria rather than metabolic phenotype. Therefore, GDM phenotyping should currently be viewed as an evolving research framework, not a replacement for established clinical guidelines.

Nevertheless, the concept has intriguing possibilities.

If researchers can reliably identify phenotypes that predict specific complications, clinicians might eventually be able to tailor monitoring intensity more precisely. For example, a metabolic pattern strongly associated with fetal overgrowth could justify closer assessment of fetal growth or earlier therapeutic escalation.

Likewise, understanding the underlying metabolic abnormality could potentially help guide lifestyle interventions. Patients whose hyperglycemia occurs alongside marked insulin resistance may ultimately benefit from a different strategy than those whose primary limitation involves insulin secretion.

Postpartum care is another potential opportunity. Because GDM increases future diabetes risk, follow-up glucose testing and ongoing prevention remain important. Yet future research could determine whether more sophisticated phenotyping improves predictions beyond established clinical risk factors.

For now, patients should not change treatment based on a presumed GDM subtype without discussing it with their healthcare team. Anyone seeking individualized medical guidance can also consult a qualified healthcare professional through Healthcare.pro.

Ultimately, personalized GDM treatment will require more than finding interesting clusters in a dataset. Researchers must demonstrate that phenotype-based decisions improve outcomes compared with current care. They will also need practical tests that clinicians can use reliably across diverse populations.

Conclusion

Research into the different metabolic phenotypes of gestational diabetes challenges the idea that every GDM diagnosis represents the same underlying condition. Studies have identified insulin-resistant, insulin-deficient, mixed, and data-driven metabolic groups, with some showing meaningful differences in pregnancy outcomes.

However, the evidence does not yet justify replacing current diagnostic or treatment approaches. Moreover, different phenotypes may still share underlying beta-cell dysfunction, and postpartum diabetes risk can remain elevated across subtypes.

The most promising possibility is therefore not a new label, but better precision. As researchers validate these metabolic patterns, GDM care could eventually move toward more individualized risk assessment, monitoring, treatment, and postpartum prevention.

Frequently Asked Questions

What are gestational diabetes phenotypes?

These GDM phenotypes are proposed subgroups based on differences in metabolic characteristics. Researchers have examined factors such as insulin resistance, insulin secretion, glucose patterns, BMI, and other clinical measures to identify these groups.

Do all patients with gestational diabetes have insulin resistance?

Pregnancy naturally increases insulin resistance, but the metabolic abnormalities associated with GDM vary. Some patients show particularly impaired insulin sensitivity, while others appear to have a greater limitation in insulin secretion. Researchers also emphasize that insulin sensitivity and secretion are closely linked.

Do different GDM phenotypes have different pregnancy risks?

Some studies suggest they do. In particular, insulin-resistant phenotypes have been associated with fetal overgrowth and higher rates of certain adverse pregnancy outcomes. However, results vary, and additional validation is needed before phenotype routinely guides clinical decisions.

Can a GDM phenotype predict type 2 diabetes after pregnancy?

Not reliably enough for routine clinical use. Research shows that multiple GDM subtypes can have increased postpartum prediabetes or diabetes risk. Therefore, recommended postpartum screening remains important regardless of presumed phenotype.

Are doctors currently treating GDM according to phenotype?

Generally, no. Current care primarily relies on established diagnostic criteria, glucose monitoring, nutrition and physical activity interventions, and medication when needed. Phenotype-guided treatment remains an active area of research rather than standard clinical practice.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.